United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total value of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00.
• On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $473.66, for a total value of $10,657,350.00.
• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $429.25, for a total transaction of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.50, for a total transaction of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total transaction of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $450.24, for a total transaction of $10,130,400.00.

United Therapeutics Trading Down 0.1%

UTHR stock traded down $0.30 during mid-day trading on Tuesday, reaching $500.00. The company’s stock had a trading volume of 483,805 shares, compared to its average volume of 578,260. The company’s 50 day moving average is $458.75 and its two-hundred day moving average is $376.11. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $502.77. The stock has a market cap of $21.53 billion, a PE ratio of 18.95, a P/E/G ratio of 4.90 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the previous year, the firm posted $6.39 EPS. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC raised its position in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. grew its stake in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares in the last quarter. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at $317,617,000. Assetmark Inc. lifted its stake in United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after acquiring an additional 197,384 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after acquiring an additional 4,145 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a report on Wednesday, September 10th. Finally, UBS Group increased their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.